Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Complement 3 targeting small interfering RNA - Argo Biopharma

Next Previous
Drug Profile

Complement 3 targeting small interfering RNA - Argo Biopharma

Alternative Names: C3 siRNA

Latest Information Update: 06 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Argo Biopharma
  • Class Anti-inflammatories; Small interfering RNA
  • Mechanism of Action Complement C3 expression modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glomerulonephritis; IgA nephropathy; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 21 Feb 2024 Complement 3 targeting small interfering RNA - Argo Biopharma is available for licensing as of 21 Feb 2024. https://www.argobiopharma.com/partnering/index.html (Argo Biopharma pipeline, February 2024)
  • 21 Feb 2024 Preclinical trials in Glomerulonephritis in China (Parenteral) prior to February 2024 (Argo Biopharma pipeline, February 2024)
  • 21 Feb 2024 Preclinical trials in IgA nephropathy in China (Parenteral) prior to February 2024 (Argo Biopharma pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top